156 related articles for article (PubMed ID: 30275706)
1. The predictive ability of plasma
Du Y; Li N; Jiao X; Li K; Yan S
Onco Targets Ther; 2018; 11():6023-6029. PubMed ID: 30275706
[TBL] [Abstract][Full Text] [Related]
2. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of circulating
Zhang K; Hong R; Xu F; Xia W; Kaping L; Qin G; Zheng Q; Lu Q; Shi YX; Yuan ZY; Wang S
Cancer Manag Res; 2018; 10():2573-2580. PubMed ID: 30147360
[TBL] [Abstract][Full Text] [Related]
4. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Fribbens C; O'Leary B; Kilburn L; Hrebien S; Garcia-Murillas I; Beaney M; Cristofanilli M; Andre F; Loi S; Loibl S; Jiang J; Bartlett CH; Koehler M; Dowsett M; Bliss JM; Johnston SR; Turner NC
J Clin Oncol; 2016 Sep; 34(25):2961-8. PubMed ID: 27269946
[TBL] [Abstract][Full Text] [Related]
5. The clinical impact of plasma estrogen receptor-1 mutation in patients with metastatic breast cancer: A meta-analysis.
Zhang X; Tian Y; Mo D; Chen W; Ding Y; Yang Y; Li X
Adv Clin Exp Med; 2024 Feb; ():. PubMed ID: 38353504
[TBL] [Abstract][Full Text] [Related]
6.
Turner NC; Swift C; Kilburn L; Fribbens C; Beaney M; Garcia-Murillas I; Budzar AU; Robertson JFR; Gradishar W; Piccart M; Schiavon G; Bliss JM; Dowsett M; Johnston SRD; Chia SK
Clin Cancer Res; 2020 Oct; 26(19):5172-5177. PubMed ID: 32546646
[TBL] [Abstract][Full Text] [Related]
7. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
8. Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer.
Bos MK; Lam SW; Motta G; Helmijr JCA; Beaufort CM; de Jonge E; Martens JWM; Boven E; Jansen MPHM; Jager A; Sleijfer S
Breast Cancer Res Treat; 2023 Jul; 200(2):271-279. PubMed ID: 37226020
[TBL] [Abstract][Full Text] [Related]
9. Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.
Clatot F; Perdrix A; Augusto L; Beaussire L; Delacour J; Calbrix C; Sefrioui D; Viailly PJ; Bubenheim M; Moldovan C; Alexandru C; Tennevet I; Rigal O; Guillemet C; Leheurteur M; Gouérant S; Petrau C; Théry JC; Picquenot JM; Veyret C; Frébourg T; Jardin F; Sarafan-Vasseur N; Di Fiore F
Oncotarget; 2016 Nov; 7(46):74448-74459. PubMed ID: 27801670
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
11. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
[TBL] [Abstract][Full Text] [Related]
12. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
[TBL] [Abstract][Full Text] [Related]
13. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen X; Meng F; Jiang R
Front Oncol; 2021; 11():746976. PubMed ID: 34900692
[TBL] [Abstract][Full Text] [Related]
17. Platelet-lymphocyte ratio acts as an independent predictor of prognosis in patients with renal cell carcinoma.
Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
Clin Chim Acta; 2018 May; 480():166-172. PubMed ID: 29462592
[TBL] [Abstract][Full Text] [Related]
18. CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients.
Crucitta S; Ruglioni M; Lorenzini G; Bargagna I; Luculli GI; Albanese I; Bilancio D; Patanè F; Fontana A; Danesi R; Del Re M
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831647
[TBL] [Abstract][Full Text] [Related]
19. Fulvestrant for hormone-sensitive metastatic breast cancer.
Lee CI; Goodwin A; Wilcken N
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011093. PubMed ID: 28043088
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer.
Lyu D; Liu B; Lan B; Sun X; Li L; Zhai J; Qian H; Ma F
Chin J Cancer Res; 2022 Aug; 34(4):343-352. PubMed ID: 36199538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
